<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4765">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781702</url>
  </required_header>
  <id_info>
    <org_study_id>DW Plb RA301</org_study_id>
    <nct_id>NCT01781702</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Pelubiprofen Tab. &amp; Celebrex Cap. in Rheumatoid Arthritis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. &amp; Celebrex Cap. for Comparative Evaluation of Safety &amp; Efficacy in Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. &amp; Celebrex Cap.
      for Comparative Evaluation of Safety &amp; Efficacy in Rheumatoid Arthritis Patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Changes in '100 mm pain VAS' value from baseline</measure>
    <time_frame>-14, 0, 14, 28, 42 day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pelubiprofen</condition>
  <condition>Celebrex</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Pelubiprofen 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pelubiprofen 30 mg, tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celebrex 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celebrex 200 mg, tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubiprofen 30 mg</intervention_name>
    <arm_group_label>Pelubiprofen 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex 200 mg</intervention_name>
    <arm_group_label>Celebrex 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males/Females aged 18~80 years

          2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis

          3. Patients who belong to ACR functional class 1, 2, 3

        Exclusion Criteria:

          1. Patients who belong to ACR functional class 4

          2. Patients who are hypersensitive to clinical trial medicines or excipient

          3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 7, 2013</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
